KRAS and cancer: However, in cancer cells expressing oncogenic forms of KRAS, the balance between the phosphorylation-dephosphorylation states of MYC is shifted toward an increased phosphorylation at Ser 62, thus reducing the amount MYC that undergoes ubiquitination and degradation.